{"name":"Progenity","slug":"progenity","ticker":"PROG","exchange":"NASDAQ","domain":"progenity.com","description":"Progenity is a biotechnology company focused on gastrointestinal (GI) drug delivery. The company's top products include Preecludia, a non-invasive prenatal test for preeclampsia, and others. Progenity is positioned to capitalize on the growing demand for non-invasive diagnostic tests and treatments.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Harry Stylli","sector":"GI Drug Delivery / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":12153000,"revenueGrowth":-79.9,"grossMargin":0,"rdSpend":29838000,"netIncome":-124115000,"cash":31215000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Progenity Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Progenity reported a net loss of $43.4 million for the fourth quarter and $173.4 million for the full year 2023.","drugName":"","sentiment":"negative"},{"date":"2023-11-15","type":"deal","headline":"Progenity Announces Collaboration with Biogen to Develop Non-Invasive Diagnostic Tests","summary":"Progenity partnered with Biogen to develop non-invasive diagnostic tests for neurological disorders.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Grants Breakthrough Device Designation to Progenity's Non-Invasive Preeclampsia Test","summary":"The FDA granted Breakthrough Device Designation to Progenity's non-invasive prenatal test for preeclampsia.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2024-12-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2024-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQdmhlNnpLX2NnbjhNV3hfR29zM1ZUMUhVRkFsUjhoNHJDbjRPenliWmFDM3BqVE9pRXlXQTRqUDNJMHQ2a2RFUFV4ZWViNnNRVGU4TTBaZFFldll2OUlxbXFwcDVjc2x5ZTk3MmtvcjA2NXRIYWR1NnNWbGt3SmlhVExZNWJEUTNMb1FaWHJpdVczS2Z2YVh1MV8xN0ZIaGhoQTN0Q3hsN0xabVdoV0FfSzdtRkRhWnAyMUN5VUVFa1QyUjlQS2c?oc=5","date":"2022-03-15","type":"trial","source":"Fierce Pharma","summary":"Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical test - Fierce Pharma","headline":"Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical test","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","Invitae","LabCorp"],"therapeuticFocus":["Gastrointestinal (GI) drug delivery","Non-invasive diagnostic tests"],"financials":{"source":"sec_edgar+yahoo","revenue":12153000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":12153000,"period":"2022-12-31"},{"value":60609000,"period":"2021-12-31"},{"value":60609000,"period":"2021-12-31"},{"value":74313000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":29838000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-124115000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":31215000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}